Purchase this article with an account.
K. B. Schaal, C. Engler, D. Thiemeyer, S. Dithmar; Anti-VEGF Therapy With Bevacizumab for Advanced Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1782. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of bevacizumab (AvastinTM) in advanced neovascular age-related macular degeneration with best corrected visual acuity (BCVA) less than 20/200.
Prospective study. After informed consent patients with advanced neovascular AMD and BCVA of 20/200 or worse receive intravitreal bevacizumab (1.25 mg/0.05ml) every 6 weeks until CNV-leakage resolves. Ophthalmic examination, visual acuity (ETDRS) and Stratus OCTTM are performed at baseline, 1 week after injection and on a monthly basis. Fluorescein angiography and regular medical check-up are also performed.
13 patients have been included in the study so far with a mean follow-up of 12 ± 6 weeks. The intravitreous injections were very well tolerated with no intraocular or systemic adverse events. On last visit, mean central retinal thickness decreased by 251µm compared to baseline. Visual acuity could be stabilised in all patients. 46.5% of patients gained at least 3 lines. 8% of patients gained ≥ 6 lines.
The intravitreal use of bevacizumab even for advanced neovascular AMD with low BCVA at baseline seems to be effective. Follow-up is ongoing to determine the durability of this favorable outcome.
This PDF is available to Subscribers Only